<DrugInformationSummary id="CDR0000767749"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Nivolumab works by binding to and blocking the protein PD-1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack the cancer cells. Nivolumab is a type of immunotherapy drug called an immune checkpoint inhibitor.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab">Nivolumab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000539733">nivolumab</TerminologyLink><GlossaryLink ref="CDR0000767747">nivolumab</GlossaryLink><USBrandNames><USBrandName>Opdivo</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>nih-VOL-yoo-mab</TermPronunciation><MediaLink ref="CDR0000771214" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000771213" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Nivolumab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Nivolumab
         is approved 
         to be used alone or with other drugs to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000574284" dictionary="Cancer.gov" audience="Patient">classic Hodgkin lymphoma</GlossaryTermRef></Strong> in adults whose cancer has come back or has gotten worse after either:<ItemizedList Style="bullet" id="_6"><ListItem>an <GlossaryTermRef href="CDR0000270733" dictionary="Cancer.gov" audience="Patient">autologous stem cell transplant</GlossaryTermRef> and treatment with <GlossaryTermRef href="CDR0000710543" dictionary="Cancer.gov" audience="Patient">brentuximab vedotin</GlossaryTermRef>¹; or</ListItem><ListItem>at least three other types of treatment including an autologous stem cell transplant¹</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000444983" dictionary="Cancer.gov" audience="Patient">colorectal cancer</GlossaryTermRef></Strong> in adults and children aged 12 years and older whose cancer is <GlossaryTermRef href="CDR0000789683" dictionary="Cancer.gov" audience="Patient">microsatellite instability-high</GlossaryTermRef> (MSI-H) or <GlossaryTermRef href="CDR0000789741" dictionary="Cancer.gov" audience="Patient">mismatch repair deficient</GlossaryTermRef> (dMMR). Nivolumab is used:<ItemizedList Style="bullet" id="_18"><ListItem>alone in patients whose cancer has spread to other parts of the body and got worse after treatment with a <GlossaryTermRef href="CDR0000386207" dictionary="Cancer.gov" audience="Patient">fluoropyrimidine</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045465" dictionary="Cancer.gov" audience="Patient">oxaliplatin</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000635811" dictionary="Cancer.gov" audience="Patient">irinotecan hydrochloride</GlossaryTermRef></ListItem><ListItem>with <GlossaryTermRef href="CDR0000535555" dictionary="Cancer.gov" audience="Patient">ipilimumab</GlossaryTermRef> in patients whose cancer has spread to other parts of the body or cannot be removed by surgery</ListItem></ItemizedList> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000444989" dictionary="Cancer.gov" audience="Patient">esophageal cancer</GlossaryTermRef> or <GlossaryTermRef href="CDR0000302458" dictionary="Cancer.gov" audience="Patient">gastroesophageal junction</GlossaryTermRef> <GlossaryTermRef href="CDR0000046216" dictionary="Cancer.gov" audience="Patient">adenocarcinoma</GlossaryTermRef>.</Strong> Nivolumab is used in adults:<ItemizedList Style="bullet" id="_15"><ListItem>for esophageal cancer or gastroesophageal junction adenocarcinoma that has been treated with a combination of <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef>  and then  surgery to completely remove the cancer, but cancer cells were found in the removed  tumor or lymph nodes</ListItem><ListItem>for <GlossaryTermRef href="CDR0000046595" dictionary="Cancer.gov" audience="Patient">squamous cell carcinoma</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000046408" dictionary="Cancer.gov" audience="Patient">esophagus</GlossaryTermRef> that cannot be removed by surgery or has spread or come back after treatment with a fluoropyrimidine and <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef>-based chemotherapy</ListItem><ListItem>for squamous cell carcinoma of the esophagus that cannot be removed by surgery or has spread to other parts of the body. It is given with either ipilimumab or a fluoropyrimidine and platinum-based chemotherapy as the first treatment.</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000454513" dictionary="Cancer.gov" audience="Patient">gastric (stomach) cancer</GlossaryTermRef></Strong>, <Strong>gastroesophageal junction adenocarcinoma</Strong>, or <Strong>esophageal cancer</Strong> that has spread. Nivolumab is used with a fluoropyrimidine and platinum-based chemotherapy.¹</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">hepatocellular carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000044242" dictionary="Cancer.gov" audience="Patient">liver cancer</GlossaryTermRef>) that cannot be removed by surgery or has spread to other parts of the body.  Nivolumab is used with ipilimumab in adults as the first treatment or after treatment with <GlossaryTermRef href="CDR0000509041" dictionary="Cancer.gov" audience="Patient">sorafenib</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044992" dictionary="Cancer.gov" audience="Patient">malignant pleural mesothelioma</GlossaryTermRef>.</Strong>  Nivolumab is used with ipilimumab as the first treatment in adults whose cancer cannot be removed by surgery.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045135" dictionary="Cancer.gov" audience="Patient">melanoma</GlossaryTermRef>.</Strong> Nivolumab is used:<ItemizedList Style="bullet" id="_7"><ListItem>alone or with ipilimumab in adults and children aged 12 years and older whose cancer cannot be removed by surgery or has spread to other parts of the body</ListItem><ListItem>as <GlossaryTermRef href="CDR0000045587" dictionary="Cancer.gov" audience="Patient">adjuvant therapy</GlossaryTermRef> in adults and children aged 12 years and older with one of the following stages of melanoma that has been completely removed by surgery: stage <GlossaryTermRef href="CDR0000045137" dictionary="Cancer.gov" audience="Patient">IIB</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045137" dictionary="Cancer.gov" audience="Patient">IIC</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045138" dictionary="Cancer.gov" audience="Patient">IIIA</GlossaryTermRef>, <GlossaryTermRef href="CDR0000793005" dictionary="Cancer.gov" audience="Patient">IIIB</GlossaryTermRef>, <GlossaryTermRef href="CDR0000793008" dictionary="Cancer.gov" audience="Patient">IIIC</GlossaryTermRef>, <GlossaryTermRef href="CDR0000793010" dictionary="Cancer.gov" audience="Patient">IIID</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045139" dictionary="Cancer.gov" audience="Patient">IV</GlossaryTermRef> melanoma</ListItem></ItemizedList></ListItem>
   
   <ListItem><Strong><GlossaryTermRef href="CDR0000045323" dictionary="Cancer.gov" audience="Patient">non-small cell lung cancer</GlossaryTermRef></Strong> in adults. Nivolumab is   used:<ItemizedList Style="bullet" id="_14"><ListItem>with platinum-based chemotherapy before surgery for <GlossaryTermRef href="CDR0000561398" dictionary="Cancer.gov" audience="Patient">early-stage cancer</GlossaryTermRef> </ListItem><ListItem>with platinum-based <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> before surgery and then alone after surgery for cancer that does not have an abnormal <GeneName>EGFR</GeneName> or <GeneName>ALK</GeneName> gene</ListItem><ListItem>as the first treatment with ipilimumab for cancer that has spread to other parts of the body and has the <GlossaryTermRef href="CDR0000797389" dictionary="Cancer.gov" audience="Patient">PD-L1</GlossaryTermRef> <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> but does not have an abnormal <GeneName><GlossaryTermRef href="CDR0000044397" dictionary="Cancer.gov" audience="Patient">EGFR</GlossaryTermRef></GeneName> or <GeneName><GlossaryTermRef href="CDR0000721252" dictionary="Cancer.gov" audience="Patient">ALK</GlossaryTermRef></GeneName> gene</ListItem><ListItem>as the first treatment with ipilimumab and platinum-based chemotherapy   for cancer that has spread to other parts of the body  or came back but does not have an abnormal <GeneName>EGFR</GeneName> or <GeneName>ALK</GeneName> gene</ListItem><ListItem>for cancer that has spread to other parts of the body and has gotten worse during or after treatment with platinum-based chemotherapy. Patients whose cancer has an abnormal <GeneName>EGFR</GeneName> or <GeneName>ALK</GeneName> gene should receive nivolumab only if their cancer got worse after treatment with <GlossaryTermRef href="CDR0000454786" dictionary="Cancer.gov" audience="Patient">FDA</GlossaryTermRef>-approved therapy for these gene mutations.</ListItem></ItemizedList> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000661352" dictionary="Cancer.gov" audience="Patient">renal cell carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000444995" dictionary="Cancer.gov" audience="Patient">kidney cancer</GlossaryTermRef>) that is <GlossaryTermRef href="CDR0000478743" dictionary="Cancer.gov" audience="Patient">advanced</GlossaryTermRef> in adults. Nivolumab is used:<ItemizedList Style="bullet" id="_8"><ListItem>who have already received <GlossaryTermRef href="CDR0000046739" dictionary="Cancer.gov" audience="Patient">angiogenesis inhibitor</GlossaryTermRef> therapy</ListItem><ListItem>with <GlossaryTermRef href="CDR0000743915" dictionary="Cancer.gov" audience="Patient">cabozantinib-s-malate</GlossaryTermRef> as the first treatment</ListItem><ListItem>with ipilimumab as the first treatment in some patients</ListItem></ItemizedList> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000597171" dictionary="Cancer.gov" audience="Patient">squamous cell carcinoma of the head and neck</GlossaryTermRef></Strong> that   has spread to other parts of the body or has come back and   got worse during or after treatment with platinum-based chemotherapy</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000783188" dictionary="Cancer.gov" audience="Patient">urothelial carcinoma</GlossaryTermRef></Strong> (a type of cancer in the bladder or urinary tract) in adults.  Nivolumab is used: <ItemizedList id="_16" Style="bullet"><ListItem>with <GlossaryTermRef href="CDR0000045230" dictionary="Cancer.gov" audience="Patient">cisplatin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000508951" dictionary="Cancer.gov" audience="Patient">gemcitabine</GlossaryTermRef> as the first treatment for cancer that cannot be removed by surgery or has spread to other parts of the body</ListItem><ListItem>after surgery to remove cancer that has a high risk of coming back</ListItem><ListItem>for cancer that has spread and was treated with platinum-based chemotherapy, but it did not work, is no longer working, or the cancer has gotten worse</ListItem></ItemizedList> </ListItem></ItemizedList>
  <Para id="_13">¹This use is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, a <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that nivolumab provides a clinical benefit in these patients.</Para><Para id="_17">Nivolumab is given by infusion. It is available in a different form, combined with hyaluronidase, that is given <GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">subcutaneously</GlossaryTermRef>. For more information, see the Drug Information Summary for <DrugRef href="CDR0000817349" url="/about-cancer/treatment/drugs/nivolumab-and-hyaluronidase-nvhy">Nivolumab and Hyaluronidase-nvhy</DrugRef>. Nivolumab is also available as a combination formulation with a drug called relatlimab. For more information, see the Drug Information Summary for <DrugRef href="CDR0000809173" url="/about-cancer/treatment/drugs/nivolumab-and-relatlimab-rmbw">Nivolumab and Relatlimab-rmbw</DrugRef>.</Para><Para id="_4">Nivolumab
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Nivolumab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/539733">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.101">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a614056.html">Nivolumab</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.102"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.103">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-nivolumab-ipilimumab-dmmr-colorectal-cancer">FDA Approval Likely to Change Initial Treatment for Some People with Advanced Colorectal Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/hodgkin-lymphoma-nivolumab-avd-first-line">Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy">Trial Establishes Preferred Treatment for Some People with Esophageal Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/new-nci-precision-medicine-trials">What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-mismatch-repair-biomarker">A Better Biomarker for Cancer Immunotherapy?</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors">Immune Checkpoint Inhibitors</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C68814">Find Clinical Trials for Nivolumab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2015-01-07</DateFirstPublished><DateLastModified>2025-05-08</DateLastModified></DrugInformationSummary>
